Literature DB >> 21602310

A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser Cohort Study.

Mark Schiffman1, Andrew G Glass, Nicolas Wentzensen, Brenda B Rush, Philip E Castle, David R Scott, Julie Buckland, Mark E Sherman, Greg Rydzak, Peter Kirk, Attila T Lorincz, Sholom Wacholder, Robert D Burk.   

Abstract

BACKGROUND: Human papillomavirus (HPV) DNA testing is more sensitive than cytology for detection of cervical intraepithelial neoplasia grade 3 and cancer (≥CIN3). Adding HPV testing to cytology is recommended for women ≥30 but long-term prospective studies of HPV testing are rare.
METHODS: Beginning in 1989-1990, ~20,000 women in a prepaid health maintenance organization (median age = 34) were followed passively by recommended annual cytology. We tested archived cervicovaginal lavage specimens collected at enrollment, primarily by MY09-MY11 PCR-based methods, for carcinogenic HPV types. We calculated positive and negative predictive values for the entire study period, and Kaplan-Meier estimates of cumulative probability for ≥CIN3, up to 18 years of follow-up.
RESULTS: We observed 47 cases of invasive cervical cancer during the study period, and 156 cases of CIN3. Predictive values and Kaplan-Meier analyses yielded the same conclusions. In women 30 and older, the reassurance against ≥CIN3 following a single negative HPV test was long-lasting (cumulative probability = 0.7% during follow-up). In this age group, a single HPV test (positive vs. negative, hazard ratio of 8.5, 95% CI = 4.8-15.1) provided greater long-term risk stratification than a single cytologic result (abnormal vs. normal, HR = 2.9, 95% CI = 1.2-6.6). The risk for ≥CIN3 was higher for HPV16 than for the average of the other carcinogenic types (hazard ratio = 2.7). CONCLUSION AND IMPACT: The data from this cohort study show the long-term predictive value of HPV testing, particularly in women ≥30, and a possible role for distinguishing particularly carcinogenic types like HPV16. ©2011 AACR

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21602310      PMCID: PMC3156084          DOI: 10.1158/1055-9965.EPI-11-0206

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  37 in total

1.  The accuracy of colposcopic biopsy: analyses from the placebo arm of the Gardasil clinical trials.

Authors:  Mark H Stoler; Michelle D Vichnin; Alex Ferenczy; Daron G Ferris; Gonzalo Perez; Jorma Paavonen; Elmar A Joura; Henning Djursing; Kristján Sigurdsson; Lucy Jefferson; Frances Alvarez; Heather L Sings; Shuang Lu; Margaret K James; Alfred Saah; Richard M Haupt
Journal:  Int J Cancer       Date:  2011-03-15       Impact factor: 7.396

2.  HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica.

Authors:  M Schiffman; R Herrero; A Hildesheim; M E Sherman; M Bratti; S Wacholder; M Alfaro; M Hutchinson; J Morales; M D Greenberg; A T Lorincz
Journal:  JAMA       Date:  2000-01-05       Impact factor: 56.272

3.  The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period.

Authors:  Susanne Kjaer; Estrid Høgdall; Kirsten Frederiksen; Christian Munk; Adriaan van den Brule; Edith Svare; Chris Meijer; Attilla Lorincz; Thomas Iftner
Journal:  Cancer Res       Date:  2006-10-23       Impact factor: 12.701

4.  Human papillomavirus infection of the cervix detected by cervicovaginal lavage and molecular hybridization: correlation with biopsy results and Papanicolaou smear.

Authors:  R D Burk; A S Kadish; S Calderin; S L Romney
Journal:  Am J Obstet Gynecol       Date:  1986-05       Impact factor: 8.661

5.  Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence.

Authors:  Susanne K Kjær; Kirsten Frederiksen; Christian Munk; Thomas Iftner
Journal:  J Natl Cancer Inst       Date:  2010-09-14       Impact factor: 13.506

6.  Comparisons of HPV DNA detection by MY09/11 PCR methods.

Authors:  Philip E Castle; Mark Schiffman; Patti E Gravitt; Hortense Kendall; Stacy Fishman; Huali Dong; Allan Hildesheim; Rolando Herrero; M Concepcion Bratti; Mark E Sherman; Attila Lorincz; John E Schussler; Robert D Burk
Journal:  J Med Virol       Date:  2002-11       Impact factor: 2.327

7.  Long-term follow-up of cervical disease in women screened by cytology and HPV testing: results from the HART study.

Authors:  D Mesher; A Szarewski; L Cadman; H Cubie; H Kitchener; D Luesley; U Menon; G Hulman; M Desai; L Ho; G Terry; A Williams; P Sasieni; J Cuzick
Journal:  Br J Cancer       Date:  2010-03-30       Impact factor: 7.640

8.  Human papillomavirus genotype specificity of hybrid capture 2.

Authors:  Philip E Castle; Diane Solomon; Cosette M Wheeler; Patti E Gravitt; Sholom Wacholder; Mark Schiffman
Journal:  J Clin Microbiol       Date:  2008-06-25       Impact factor: 5.948

9.  Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections.

Authors:  Ana Cecilia Rodríguez; Mark Schiffman; Rolando Herrero; Sholom Wacholder; Allan Hildesheim; Philip E Castle; Diane Solomon; Robert Burk
Journal:  J Natl Cancer Inst       Date:  2008-03-25       Impact factor: 13.506

10.  Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants.

Authors:  Nicolas Wentzensen; Mark Schiffman; Terence Dunn; Rosemary E Zuna; Michael A Gold; Richard A Allen; Roy Zhang; Mark E Sherman; Sholom Wacholder; Joan Walker; Sophia S Wang
Journal:  Int J Cancer       Date:  2009-11-01       Impact factor: 7.396

View more
  59 in total

1.  Human papillomavirus genotype-specific prevalence across the continuum of cervical neoplasia and cancer.

Authors:  Nancy E Joste; Brigitte M Ronnett; William C Hunt; Amanda Pearse; Erika Langsfeld; Thomas Leete; MaryAnn Jaramillo; Mark H Stoler; Philip E Castle; Cosette M Wheeler
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-11-02       Impact factor: 4.254

2.  A Suggested Approach to Simplify and Improve Cervical Screening in the United States.

Authors:  Mark Schiffman; Nicolas Wentzensen
Journal:  J Low Genit Tract Dis       Date:  2016-01       Impact factor: 1.925

3.  Improving the Utilization of Human Papillomavirus and Cervical Cytology Co-testing for Cervical Cancer Screening in an Obstetrics and Gynecology Resident Clinic.

Authors:  Kurt Yoshino; Maxine Karimoto; Christina Marzo; Bliss Kaneshiro; Mark Hiraoka
Journal:  Hawaii J Med Public Health       Date:  2015-08

4.  Point: cervical cancer screening guidelines should consider observational data on screening efficacy in older women.

Authors:  Alison S Rustagi; Aruna Kamineni; Noel S Weiss
Journal:  Am J Epidemiol       Date:  2013-08-21       Impact factor: 4.897

5.  An Observational Study of Deep Learning and Automated Evaluation of Cervical Images for Cancer Screening.

Authors:  Liming Hu; David Bell; Sameer Antani; Zhiyun Xue; Kai Yu; Matthew P Horning; Noni Gachuhi; Benjamin Wilson; Mayoore S Jaiswal; Brian Befano; L Rodney Long; Rolando Herrero; Mark H Einstein; Robert D Burk; Maria Demarco; Julia C Gage; Ana Cecilia Rodriguez; Nicolas Wentzensen; Mark Schiffman
Journal:  J Natl Cancer Inst       Date:  2019-09-01       Impact factor: 13.506

6.  No evidence for synergy between human papillomavirus genotypes for the risk of high-grade squamous intraepithelial lesions in a large population-based study.

Authors:  Nicolas Wentzensen; Martha Nason; Mark Schiffman; Lori Dodd; William C Hunt; Cosette M Wheeler
Journal:  J Infect Dis       Date:  2013-10-31       Impact factor: 5.226

7.  American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer.

Authors:  Debbie Saslow; Diane Solomon; Herschel W Lawson; Maureen Killackey; Shalini L Kulasingam; Joanna Cain; Francisco A R Garcia; Ann T Moriarty; Alan G Waxman; David C Wilbur; Nicolas Wentzensen; Levi S Downs; Mark Spitzer; Anna-Barbara Moscicki; Eduardo L Franco; Mark H Stoler; Mark Schiffman; Philip E Castle; Evan R Myers
Journal:  CA Cancer J Clin       Date:  2012-03-14       Impact factor: 508.702

8.  Screening: Cervical cancer--should we abandon cytology for screening?

Authors:  Chris J L M Meijer; Johannes Berkhof
Journal:  Nat Rev Clin Oncol       Date:  2012-09-11       Impact factor: 66.675

9.  Direct human papillomavirus E6 whole-cell enzyme-linked immunosorbent assay for objective measurement of E6 oncoproteins in cytology samples.

Authors:  Yi-Shan Yang; Karen Smith-McCune; Teresa M Darragh; Yvonne Lai; Ju-Hwa Lin; Ting-Chang Chang; Hsiao-Yun Guo; Tiea Kesler; Alicia Carter; Philip E Castle; Shuling Cheng
Journal:  Clin Vaccine Immunol       Date:  2012-07-18

10.  Risk Stratification Using Human Papillomavirus Testing among Women with Equivocally Abnormal Cytology: Results from a State-Wide Surveillance Program.

Authors:  Julia C Gage; William C Hunt; Mark Schiffman; Hormuzd A Katki; Li C Cheung; Jack Cuzick; Orrin Myers; Philip E Castle; Cosette M Wheeler
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-10-30       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.